15.12
Modele farmakodynamiczne: Logarytmiczny model zależności stężenie–efekt
Model logarytmiczno-liniowy stanowi ramy farmakologiczne służące do opisu zależności między stężeniem leku a jego efektem. Model ten jest szczególnie…
Model log-liniowy zakłada, że efekt jest bezpośrednio proporcjonalny do logarytmu stężenia leku.
Efekt E jest dany przez następujące równanie. Tutaj S oznacza efekt wywołany przez stężenie leku jednostkowego, C to stężenie leku w osoczu, a E0 oznacza efekt bazowy.
Gdy maksymalny efekt, Emax, wynosi od 20 do 80%, wykres logarytmu stężenia leku względem efektu wydaje się niemal liniowy.
Co istotne, model nie jest w stanie przewidzieć maksymalnego stężenia E ani efektu przy zerowym stężeniu leku.
Jednak jest wykorzystywany do przewidywania zależności stężenia i efektu dla leków takich jak warfaryna i propranolol.
Na przykład wykres logaritmicznego stężenia propranololu w osoczu oraz procentowy blok tachykardii wywołanej wysiłkiem jest liniowy zarówno dla dróg dożylnych, jak i doustnych.
W rezultacie zwiększenie stężenia propranololu skutecznie zmniejsza tachykardię wywołaną wysiłkiem, a droga dożylna wykazuje bardziej wyraźną i spójną reakcję.
View the full transcript and gain access to JoVE Core videos
Q1: What is the log-linear model in pharmacodynamics?
The log-linear model describes the relationship between drug concentration and its effect by assuming the effect is directly proportional to the logarithm of drug concentration. It uses the equation E = S × log(C) + E0, where S represents the effect per unit concentration, C is plasma drug concentration, and E0 is baseline effect. This model is particularly useful when drug effects range between 20% and 80% of maximum effect.
Q2: When is the log-linear model most applicable in drug analysis?
The log-linear model is most applicable when observed drug effects fall between 20% and 80% of the maximum effect (Emax), where the relationship between log drug concentration and effect appears nearly linear. Within this range, the model accurately predicts concentration-effect relationships for drugs like warfarin and propranolol, making it valuable for understanding pharmacodynamic responses in clinical settings.
Q3: What are the limitations of the log-linear pharmacodynamic model?
The log-linear model cannot predict the maximum possible effect (Emax) or the effect at zero drug concentration, limiting its applicability in complete pharmacodynamic analyses. These limitations mean the model is restricted to predicting concentration-effect relationships within the linear range and cannot extrapolate to extreme effect values or baseline conditions.
Q4: How does propranolol concentration affect exercise-induced tachycardia?
Propranolol demonstrates a linear concentration-effect relationship with exercise-induced tachycardia when plotted on a logarithmic scale. Increasing propranolol concentration effectively reduces tachycardia by blocking β-adrenergic receptors. The intravenous route produces more pronounced and consistent responses compared to oral administration due to reduced variability in bioavailability and plasma concentration.
Q5: Why does intravenous propranolol show a more consistent response than oral administration?
Intravenous propranolol administration produces more consistent and pronounced responses because it avoids the variability associated with oral bioavailability and absorption. IV administration results in more predictable plasma concentrations, allowing the log-linear model to accurately describe the concentration-effect relationship. Oral routes introduce additional variables that reduce response consistency.
Q6: Which drugs are effectively modeled using the log-linear concentration-effect approach?
Warfarin and propranolol are primary examples of drugs effectively modeled using the log-linear approach. Both drugs demonstrate linear relationships between log plasma concentration and their pharmacological effects within the 20-80% Emax range. This makes the log-linear model particularly valuable for predicting and understanding the concentration-effect relationships of these commonly used medications.
Q7: How does the log-linear model differ from other pharmacodynamic models?
The log-linear model assumes a linear relationship between log drug concentration and effect, differing from models that describe sigmoidal or non-linear relationships. Unlike the Emax model, the log-linear model cannot predict maximum effect or baseline response. It is specifically designed for the middle range of drug effects and provides a simplified approach to concentration-effect prediction within defined boundaries.